TY - JOUR T1 - Levofloxacin pharmacokinetics and pharmacodynamics and outcome in MDR-TB patients JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.02107-2018 SP - 1802107 AU - Samiksha Ghimire AU - Bhagwan Maharjan AU - Erwin M. Jongedijk AU - Jos G.W. Kosterink AU - Gokarna R. Ghimire AU - Daan J. Touw AU - Tjip S. van der Werf AU - Bhabana Shrestha AU - Jan-Willem C. Alffenaar Y1 - 2019/01/01 UR - http://erj.ersjournals.com/content/early/2019/01/02/13993003.02107-2018.abstract N2 - Fluoroquinolones (levofloxacin and moxifloxacin) belong to the class A drugs for treating multi-drug resistant tuberculosis (MDR-TB), characterised by resistance to both rifampicin and isoniazid [1]. The drugs have become a mainstay in both longer and shorter MDR-TB regimens, as well as isoniazid resistance [1, 2]. Despite this potential, currently used doses have become a major concern due to sub-therapeutic concentrations achieved, leading to acquired drug resistance [3–5].FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Ghimire has nothing to disclose.Conflict of interest: Dr. Maharjan has nothing to disclose.Conflict of interest: Dr. Jongedijk has nothing to disclose.Conflict of interest: Dr. Kosterink has nothing to disclose.Conflict of interest: Dr. Ghimire has nothing to disclose.Conflict of interest: Dr. Touw has nothing to disclose.Conflict of interest: Dr. van der Werf has nothing to disclose.Conflict of interest: Dr. Shrestha has nothing to disclose.Conflict of interest: Dr. Alffenaar has nothing to disclose. ER -